Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that commercially available dyes penetrate up to 1.2 mm into human skin, with Indocyanine Green binding to cell proteins and showing a shift in absorption peak.

This study found that a single dose of 1 mg/kg dexamethasone promoted wound healing in septic mice but delayed it in normal mice.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

AGC2-1 protein is essential for root hair growth in Arabidopsis.

Taking 1 mg finasteride for a year reduces dihydrotestosterone levels in men with early hair loss, but doesn't change their metabolic state.

This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.

This study found that 1mg/day oral finasteride significantly improved androgenetic alopecia in Chinese men, with a higher efficacy rate compared to placebo and minimal adverse effects.

This study found that 1mg/d oral finasteride was effective and safe for treating androgenetic alopecia in men, with better results observed in patients aged 26 or younger.

This study found that 1% minoxidil topical solution led to terminal hair regrowth in some patients with alopecia areata, though it was only cosmetically acceptable in less than half of those cases.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This case report hypothesizes that finasteride 1mg daily may influence melasma development in men by affecting estrogen and progesterone levels in the skin.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This study observed smaller reductions in PSA levels in men under 40 taking finasteride 1mg/day compared to older age groups, without changes in testosterone levels.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This article discusses the effects of 1mg/day finasteride on PSA levels and its implications for prostate cancer diagnosis, reporting no new clinical results; further investigation is suggested.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study found that finasteride (1 mg/day) appeared to reverse the shortening of the hair cycle in androgen sensitive sites but did not convert miniaturized hair into terminal hair.

This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.

This study identified a new lignan and 21 known compounds from Asiasarum heterotropoides roots, with two compounds showing potential anticancer activity by influencing NO production, FOXP3 expression, and HIF-1α activity in vitro.

This study found that finasteride 1 mg per day improved hair growth and slowed hair loss in Japanese men with male pattern hair loss compared to lower doses and placebo.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This article narrates a case where a patient with androgenetic alopecia faced high out-of-pocket costs for finasteride 1 mg and sought to reduce expenses by requesting a prescription for 5 mg tablets typically used for BPH, which are covered by insurance.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.